Jude Onyia - 01 Jun 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Scientific Officer
Issuer ticker: NBIX
Reported as of: 01 Jun 2026
Net transaction value: -$1,762,710
SEC form: 4
Accepted by SEC: 02 Jun 2026, 18:08:16 UTC
Prior SEC filing: 29 May 2026
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Jude Onyia filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 02 Jun 2026.

Key facts

This page summarizes Jude Onyia's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2026, 18:08.

Change

Previous filing in this sequence was filed on 29 May 2026.
Current net transaction value: -$1,762,710.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001894425 Primary reporting owner

Onyia Jude

Relationship: Chief Scientific Officer
Address: 6027 EDGEWOOD BEND CT., SAN DIEGO
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,000
Change %: +43%
Price: $84.74^*
Shares after: 36,846
Date: 01 Jun 2026
Ownership: Direct

NBIX transaction

Common Stock

Sale

Transaction value: $1,762,710
Shares: -11,000
Change %: -30%
Price: $160.25
Shares after: 25,846
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Non-Qualified Stock Option

Options Exercise

Transaction value
Shares: -11,000
Change %: -45%
Price: $0.000000^*
Shares after: 13,268
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,000
Exercise price: $84.74
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F3

Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.